About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Are We Finally Getting Somewhere With Health Literacy in the U.S.?
One-third of patients cannot read or understand their prescription labels and
related medication materials. Dr. Parker, a clinician educator, discusses her
collaborations with other professionals in the effort to tackle the widespread
problem of limited health literacy.
Sonja Sherritze, Editor, P&T
Practical Strategies to Improve Communication With Patients
Poor health literacy is a major cause of the inability of patients to take their
medications properly. This article discusses strategies that can be implemented at both the individual and the system levels.
Adam Carlisle, MD; Kara L. Jacobson, MPH; Lorenzo Di Francesco, MD; and Ruth M. Parker, MD
Maintenance treatment with rituximab has been found to improve outcomes in
patients with both untreated and relapsed follicular lymphoma. However, more
studies are needed to determine the optimal timing, schedule, and duration of
Nathan H. Fowler, MD
15th International Congress of Parkinson’s Disease and Movement Disorders and Inaugural Melanoma and Cutaneous Malignancy Meeting
At the movement disorders meeting, therapies included incobotulinumtoxinA
(Xeomin) for blepharospasm and cervical dystonia, a rotigotine patch (Neupro)
for restless legs syndrome, and a carbidopa/levodopa capsule (IPX066) for
Parkinson’s disease. Topics covered at the melanoma meeting included interferon and three novel intralesional therapies (Allovectin, OncoVex, and Rose Bengal).
Staff members often feel too intimidated to question superiors about potential prescribing errors.
Matthew Grissinger, RPh, FASCP
Who Is Asking for the Information Anyway?
New HIPAA, HITECH provisions will make things more complicated for pharmacists and their software systems.
Brilinta for ACS, Xarelto for DVT, and Arcapta Neohaler for COPD
Marvin M. Goldenberg, PhD, RPh, MS
FDA approvals, drug indications, and updates
Vorapaxar, an investigational antiplatelet agent
Younos Abdulsattar, PharmD, BCPS; Theologia Ternas, PharmD; and Danielle Garcia, PharmD